Voya Investment Management LLC Reduces Position in Becton, Dickinson and Company $BDX

Voya Investment Management LLC trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 67,540 shares of the medical instruments supplier’s stock after selling 4,779 shares during the quarter. Voya Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $12,641,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. CW Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 85.3% in the first quarter. CW Advisors LLC now owns 5,600 shares of the medical instruments supplier’s stock worth $1,283,000 after purchasing an additional 2,578 shares during the last quarter. Compound Planning Inc. increased its stake in Becton, Dickinson and Company by 33.3% in the 1st quarter. Compound Planning Inc. now owns 1,408 shares of the medical instruments supplier’s stock worth $323,000 after buying an additional 352 shares during the period. AlphaQuest LLC lifted its holdings in Becton, Dickinson and Company by 3,563.3% during the 1st quarter. AlphaQuest LLC now owns 1,099 shares of the medical instruments supplier’s stock valued at $252,000 after buying an additional 1,069 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Becton, Dickinson and Company by 7.9% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 14,136 shares of the medical instruments supplier’s stock valued at $3,238,000 after buying an additional 1,036 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the sale, the executive vice president owned 13,105 shares of the company’s stock, valued at approximately $2,568,973.15. The trade was a 4.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. The trade was a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 1,036 shares of company stock valued at $197,225. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.5%

NYSE:BDX opened at $196.59 on Tuesday. The company’s 50-day simple moving average is $189.68 and its 200-day simple moving average is $185.73. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The stock has a market capitalization of $56.01 billion, a P/E ratio of 33.72, a P/E/G ratio of 1.81 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.32 billion during the quarter. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Argus lifted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Stifel Nicolaus reduced their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Jefferies Financial Group raised their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $205.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.